ClinicalTrials.gg
CompletedNCT02997202Updated Jan 17, 2025Results posted

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

A Phase 3 interventional study of gilteritinib and Placebo in Acute Myeloid Leukemia, sponsored by Astellas Pharma Global Development, Inc.. Completed at 118 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-17.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
356
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute — 13 open to participants now, 15 under way, 6 of them phase 3. gilteritinib · Leukemia, Myeloid, Acute.

Enrollment
8th of 31
356 · median 97
Started
2017
with 2 others
Phase 3
8 of 31
3 open now
Registered
9th of 31
by date
Lead sponsor
10 of 31
Astellas Pharma Global Development, Inc.

Among the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, this one is the 8th largest by enrollment, is one of 3 that started in 2017, is one of 8 in phase 3, and was the 9th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

13 of the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About gilteritinib

gilteritinib: first FDA approval 2018 (XOSPATA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The purpose of this study was to compare relapse-free survival between participants with FLT3/ITD AML in first morphologic complete remission (CR1) who underwent hematopoietic stem cell transplant (HCT) and were randomized to receive gilteritinib or placebo beginning after the time of engraftment for a two year period.

Read the detailed description

Participants with FLT3/ITD AML in first morphologic complete remission (CR1) undergone allogeneic hematopoietic stem cell transplant (HCT) were randomized to receive gilteritinib or placebo 30 to 90 days after HCT for a two year period. Participants wiere stratified according to: 1) conditioning regimen intensity (myeloablative vs. reduced intensity/non-myeloablative), 2) time from first day of hematopoietic cell infusion to randomization (30-60 days vs. 61-90 days) and 3) presence vs absence of or unknown minimal residual disease (MRD) from the most recent pre-registration bone marrow (BM) aspirate.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • Gilteritinib
  • ASP2215
  • Safety and Efficacy
  • Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Registration Inclusion Criteria

  • Participant is considered a suitable candidate for HCT and has an acceptable source of allogeneic donor stem cells, as defined per institutional practice ( HCT for any donor source [matched sibling, unrelated donor (URD), mismatched URD, related haploidentical, or umbilical cord blood] and any graft source [umbilical cord, BM, peripheral blood (PB)], and any conditioning [myeloablative conditioning (MAC), reduced intensity conditioning (RIC), or non-myeloablative conditioning (NMA)] will be permitted).
  • Participant is considered a legal adult by local regulation at the time of signing form (ICF).
  • Participant consents to allow access to diagnostic BM aspirate or PB sample and/or the DNA derived from that sample, if available, that may be used to validate a companion diagnostic that is being developed in parallel with gilteritinib.
  • Participant has confirmed, morphologically documented AML in CR1. For the purposes of registration, CR1 will be defined as \< 5% blasts in the BM with no morphologic characteristics of acute leukemia (e.g., Auer Rods) in the BM with no evidence of extramedullary disease such as central nervous system involvement or granulocytic sarcoma.

    • Participant has not received more than 2 cycles of induction chemotherapy to achieve CR1. The induction cycles can be the same regimen or different regimens. The regimen(s) may contain conventional agents, agents, or a combination of both.
    • Participants with CR with incomplete count recovery (CRp or CRi) are allowed. Incomplete recovery (CRp) is defined as CR with platelet count \< 100 x 109/L. Incomplete blood count recovery (CRi) is defined as CR with residual neutropenia \< 1 x 109/L with or without complete platelet recovery. Red blood cell count (RBC) and platelet transfusion independence is not required.
    • The maximum time allowed from establishment of CR1 to registration is 12 months.
  • Participant has presence of the FLT3/ITD activating mutation in the BM or PB as determined by the local institution at diagnosis.
  • Participant must meet the following criteria as indicated on the clinical laboratory tests:

    • Serum creatinine within normal range, or if serum creatinine outside normal range, then (GFR) > 40 mL/min/1.73m2 as calculated with the equation with adjustment if total body weight is ≥ 125% of ideal body weight.
    • Total (TBL) ≤ 2.5 mg/dL, except for participants with Gilbert's syndrome.
    • Serum and/or alanine aminotransferase (ALT) \< 3 x institutional (ULN).
  • Participant has at rest ≥ 40%.
  • Participant has diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for ) ≥ 50% predicted and/or (FEV1) ≥ 50% predicted.
  • Female participants must either:

    • Be of non-:
    • (defined as at least 1 year without menses) prior to screening or
    • documented as surgically sterilized (at least 1 month prior to the screening visit)
  • Or, if of childbearing potential,

    • Agree not to try to become pregnant during the study for 6 months after the final study drug administration
    • And have a negative serum pregnancy test at screening
    • And, if heterosexually active, agree to consistently use highly effective per locally accepted standards in addition to a barrier method starting at screening and throughout the study period and for 6 months after the final study drug administration.
    • For United Kingdom sites:
    • Highly effective forms of birth control include:
    • Consistent and correct usage of established hormonal contraceptives that inhibit ovulation
    • Established intrauterine device (IUD) or intrauterine system (IUS)
  • Female participants must agree not to breastfeed or donate ova throughout the study drug treatment period and for 6 months after the final study drug administration.
  • Male participants (even if surgically sterilized), and partners who are women of childbearing potential must be using highly effective contraception in addition to a barrier method throughout the study drug treatment period and for 127 days after the final study drug administration.

    • For United Kingdom sites:
    • Highly effective forms of birth control include:
    • Consistent and correct usage of established hormonal contraceptives that inhibit ovulation
    • Established IUD or IUS
    • Vasectomy (A vasectomy is a highly effective contraception method provided the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used.)
    • Male is sterile due to a bilateral orchiectomy
  • Male participants must not donate sperm throughout the study drug treatment period and for 127 days after the final study drug administration.
  • Participant is able to take an oral medication.
  • Participant agrees not to participate in another interventional study while on treatment.

Randomization Inclusion Criteria

  • Participant is ≥ 30 days and ≤ 90 days from hematopoietic cell infusion.
  • Participant has achieved engraftment. Engraftment is defined as ≥ 500 cells/μL and platelets ≥ 20000/μL on 3 consecutive measurements (each occurring at least 1 day apart). The participant must not have had a platelet transfusion within 7 days prior to the first measurement.
  • Participant has confirmed ongoing morphologically documented AML in CR1. For the purposes of randomization, CR1 will be defined as \< 5% blasts with no morphologic characteristics of acute leukemia (e.g., Auer Rods) in the BM with no evidence of extramedullary disease such as central nervous system involvement or granulocytic sarcoma.
  • Participant meets the following criteria as indicated on the clinical laboratory tests:

    • Serum creatinine within normal range, or if serum creatinine outside normal range, then GFR > 40 mL/min/1.73m2 as calculated with the Cockcroft-Gault equation with adjustment if total body weight is ≥ 125% of ideal body weight.
    • TBL \< 2.5 mg/dL, except for participants with Gilbert's syndrome.
    • Serum AST and/or ALT \< 3 x institutional ULN.
    • Serum potassium and magnesium ≥ the institutional lower limit of normal (LLN).
  • If the participant has developed overall grades II-IV acute , the following criteria must be met to be randomized:

    • No requirement of > 0.5 mg/kg of prednisone (or equivalent) daily dose within 1 week of randomization
    • No escalation of systemic in terms of increase of or addition of new agent / modality within 2 weeks of randomization. (Note that increasing calcineurin inhibitors or sirolimus to achieve therapeutic trough levels is allowed.) Topical skin and topical gastrointestinal steroids are allowed.
  • Participant is able to take oral medication.

Registration Exclusion Criteria

  • Participant has had a prior allogeneic transplant.
  • Participant has performance status score \< 70% .
  • Participant requires treatment with concomitant drugs that are strong inducers of within 14 days of start of study drug.
  • Participant requires treatment with concomitant drugs that target serotonin 5-hydroxytryptamine receptor 1 (5HT1R) or 5-hydroxytryptamine receptor 2B (5HT2BR) or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the participant.
  • Participant has a Fridericia- interval (QTcF) > 450 msec (average of triplicate determinations) per central read.
  • Participant has long QT Syndrome at screening.
  • Participant has a known infection with (HIV).
  • Participant has active infection as determined by NAAT or surface antigen assay. Participants who have acquired immunity from past exposure (HBcAb positive / HBsAb positive / HBsAg negative) are eligible.
  • Participant has active infection as determined by NAAT. NAAT must be performed if the participant has positive serology for hepatitis C. Participants who have had past exposure and have no detectable virus either through spontaneous clearance or treatment are eligible.
  • Participant has an uncontrolled infection. If a bacterial or viral infection is present, the participant must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to registration. If a fungal infection is present, the participant must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to registration.

    • Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection.
    • Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
  • Participant has had a myocardial infarction within 6 months prior to registration or (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia.
  • Participant has a serious medical or psychiatric illness likely to interfere with participation in this clinical study.
  • Participant is breast feeding or pregnant.
  • Participant has prior , except lobular breast carcinoma in situ, fully resected basal cell or squamous cell carcinoma of skin or treated cervical carcinoma in situ.

Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer treated with curative intent \< 5 years previously will not be allowed.

Randomization Exclusion Criteria

  • Participant requires treatment with concomitant drugs that are strong inducers of CYP3A within 14 days of starting study drug.
  • Participant requires treatment with concomitant drugs that target serotonin 5HT1R or 5HT2BR or sigma nonspecific receptor with the exception of drugs that are considered by the investigator to be absolutely essential for the care of the participant and for which no acceptable alternative exists.
  • Participant has a QTcF interval > 450 msec (average of triplicate determinations) by central read.
  • Participant has a need for supplemental oxygen with the exception of using previously existing non-invasive continuous positive airway pressure (CPAP) at night.
  • Participant has used investigational agents within 4 weeks of randomization.
  • Participant has used experimental therapy for acute GVHD within 4 weeks of randomization. If unsure of the definition of "experimental", discussion with one of the protocol chairs is recommended.
  • Participant has an uncontrolled infection. If a bacterial or viral infection is present, the participant must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to randomization. If a fungal infection is present, the participant must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to randomization.

    • Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection.
    • Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
356 participants (actual)

Study arms

  • Experimental
    Gilteritinib

    Participants received gilteritinib 120 milligrams (mg) (three tablets of 40 mg) orally, once daily (QD) for up to 2 years or until a protocol-defined discontinuation criterion was met.

    Drug: gilteritinib

  • Placebo comparator
    Placebo

    Participants received gilteritinib matching placebo orally, QD for up to 2 years or until a protocol-defined discontinuation criterion was met.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Relapse-free Survival (RFS)

    RFS was defined as the time from the date of randomization until the date of documented morphological relapse, or death from any cause, whichever occurred first. Morphological relapse was defined as documentation of any of the following events: * BM blasts ≥ 5% (not attributable to regenerating BM) * Any circulating blasts (not attributable to regenerating BM or growth factors) * Presence of extramedullary blast foci per Revised International Working Group (RIWG) criteria * The earliest date of any of the relapse event was used for RFS.

    Time frame: From the date of randomization up to 64 months and 22 days

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from randomization until the date of death from any cause (death date - first dose date + 1). For a Participant who were not known to have died by the end of study follow-up, OS was censored at the date of last contact (date of last contact - first dose date + 1).

    Time frame: From the date of randomization up to 64 months and 22 day

  2. Number of Participants With Treatment Emergent Adverse Events (TEAE)

    An Adverse event (AE) was any untoward medical occurrence in a participant administered a study drug, and which did not have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether considered related to the medicinal product. TEAE defined as an AE event observed through 30 days after the last dose.

    Time frame: From the date of randomization through 30 days after the last dose, up to 25 months and 22 days

  3. Karnofsky Performance Status Scores

    KPS scores of participants were reported. KPS was a standard way of measuring ability of cancer participants to perform ordinary tasks. It was 11 level score which ranged between 0-100%. 100 =Normal, no complaints, no evidence of disease 90 =Able to carry on normal activity, minor signs or symptoms of disease 80 =Normal activity with effort, some signs or symptoms of disease 70 =Care for self, unable to carry on normal activity or to do work 60 =Required occasional assistance but was able to care for most of his needs 50 =Required considerable assistance \& frequent medical care 40 =Disabled, required special care \& assistance 30 = Severely disabled, hospitalization indicated, although death not imminent 20 =Very sick, hospitalization necessary, active supportive treatment necessary 10 =moribund fatal processes progressing rapidly 0 =Dead.

    Time frame: Baseline, month 24

  4. Percentage of Participants With Non-relapse Mortality (NRM)

    NRM was defined as death from any cause other than relapse or disease progression (DP). Relapse was defined as documentation of any of the following events: * BM blasts ≥ 5% (not attributable to regenerating BM) * Any circulating blasts (not attributable to regenerating BM or growth factors) * Presence of extramedullary blast foci per RIWG criteria * The earliest date of any of the relapse event were used for RFS. DP: \>=20% increase in sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline, sum must also be absolute increase of \>=5 mm. Unequivocal progression of existing non-target lesions. Appearance of at least 1 new lesion. Incidence of NRM was estimated using the cumulative incidence function, treating relapse/progression as a competing risk.

    Time frame: From the date of randomization up to 64 months and 22 days

  5. Event-free Survival (EFS)

    EFS: Time from date of randomization until documented relapse, or premature discontinuation of treatment or initiation of other anti-leukemic treatment or death from any cause, whichever occurred first. Relapse was defined as documentation of any of following events: * BM blasts ≥ 5% (not attributable to regenerating BM) * Any circulating blasts (not attributable to regenerating BM or growth factors) * Presence of extramedullary blast foci per RIWG criteria * The earliest date of any of relapse event were used for RFS. Anti-leukemic treatment was defined as hypomethylating agents, chemotherapy, oral anticancer agents, Donor lymphocyte infusion (DLI) or cellular therapies given because of detectable disease, not meeting R-IWG criteria for relapse.

    Time frame: From the date of randomization up to 64 months and 22 days

  6. Percentage of Participants With Treatment Emergent Acute Graft vs. Host Disease (aGVHD)

    The cumulative incidence at 6 months after randomization of grades II-IV and grades III-IV aGVHD were reported, treating death prior to aGVHD as the competing risk. It was graded according to diagnosis and severity scoring used by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). The acute GVHD algorithm calculated the grade based on the organ (skin, gastrointestinal (GI)and liver) stage and etiology/biopsy reported on the weekly GVHD form. Grade I aGVHD was defined as Skin stage of 1-2 and stage 0 for both GI and liver organs. Grade II aGVHD was stage 3 of skin, or stage 1 of GI, or stage 1 of liver. Grade III is stage 2-4 for GI, or stage 2-3 of liver. Grade IV was stage 4 of skin, or stage 4 of liver. Grade IV was the worst outcome. Treatment emergent was defined as an event observed through 30 days after the last dose.

    Time frame: From the date of randomization up to 6 months

  7. Percentage of Participants With Treatment Emergent Chronic GVHD at 12 Months

    Chronic GVHD was graded according to diagnosis and severity scoring from the National Institute of Health (NIH) 2014 Consensus Criteria. Eight organs - skin, mouth, liver, upper and lower gastrointestinal, esophagus, lung, eye, and joint/fascia were scored on a 0-3 scale to reflect degree of chronic GVHD involvement, where 0 = no involvement/no symptoms \& 3 indicated the worst symptom. This system staged severity in each individual organ, and then a global score defined as mild, moderate or severe, based on number of organs involved and organ severity score was calculated. The cumulative incidence of chronic GVHD (mild, moderate, severe) at 12 months after randomization was reported, treating death prior to chronic GVHD as the competing risk. Treatment emergent was defined as an event observed through 30 days after the last dose.

    Time frame: From the date of randomization up to 12 months

  8. Percentage of Participants With Treatment Emergent Chronic GVHD at 24 Months

    Chronic GVHD was graded according to diagnosis and severity scoring from the NIH 2014 Consensus Criteria. Eight organs- skin, mouth, liver, upper and lower gastrointestinal, esophagus, lung, eye, and joint/fascia are scored on a 0-3 scale to reflect degree of chronic GVHD involvement where 0 = no involvement/no symptoms \& 3 indicated the worst symptom. This system staged severity in each individual organ, and then a global score defined as mild, moderate or severe, based on number of organs involved and organ severity score was calculated. The cumulative incidence of chronic GVHD (mild, moderate, severe) at 24 months after randomization was reported, treating death prior to chronic GVHD as the competing risk. Treatment emergent was defined as an event observed through 30 days after the last dose.

    Time frame: From the date of randomization up to 24 months

  9. Percentage of Participants With FMS-like Tyrosine Kinase 3/Internal Tandem Duplication (FLT3/ITD) Minimal Residual Disease (MRD)

    The presence of MRD was considered Detectable in participants who were FLT3/ITD MRD undetectable prior to randomization if log10-transformed overall FLT3/ITD mutation ratio greater than -4 otherwise presence of MRD was considered Not Detectable. Participants who had detectable FLT3/ITD MRD prior to randomization were considered eradicated if log10-transformed overall FLT3/ITD mutation ratio ≤ -4. Incidence of MRD Eradication and Detection were estimated using the cumulative incidence function, treating death during MRD assessment period without documentation of MRD event as competing risk.

    Time frame: From the date of randomization up to 64 months and 22 days

  10. Percentage of Participants With Relapse

    Cumulative incidence of relapse was reported, treating death in remission as a competing risk. Relapse was defined as documentation of any of the following events: * BM blasts ≥ 5% (not attributable to regenerating BM) * Any circulating blasts (not attributable to regenerating BM or growth factors) * Presence of extramedullary blast foci per RIWG criteria * The earliest date of any of the relapse event were used for RFS.

    Time frame: From the date of randomization up to 64 months and 22 days

  11. Percentage of Participants With Treatment Emergent Infection by Severity.

    Severity of Infection was assessed based on the following criteria: Grade 1-Mild Asymptomatic or mild symptoms, clinical or diagnostic observations noted intervention not indicated. Grade 2-Moderate Local or noninvasive intervention indicated. Grade 3-Severe Medically significant but not immediately life threatening, hospitalization or prolonged hospitalization. Grade 4-Life Threatening Life threatening consequences, urgent intervention indicated. Grade 5-Death related to the AE. Cumulative incidence of grade 3 to 5 infections were reported, treating death (grade 5) as a competing event. Treatment emergent was defined as an event observed through 30 days after the last dose.

    Time frame: From the date of randomization through 30 days after the last dose, up to 25 months and 22 days

07

Results

Posted Sep 19, 2024

Participant flow

Participants with FMS-like tyrosine kinase 3/Internal tandem duplication (FLT3/ITD) acute myeloid leukemia (AML) in first morphological complete remission (CR1) including complete remission with incomplete platelet recovery (CRp) \& complete remission with incomplete hematologic recovery (CRi) undergoing allogeneic hematopoietic cell transplant (HCT) were enrolled in the study.

Participant flow — Overall Study
MilestoneGilteritinibPlacebo
Started178178
Safety analysis population178177
Intent to treat (itt) population178178
Completed122116
Not completed5662
Withdrew: Miscellaneous22
Withdrew: Withdrawal by subject812
Withdrew: Lost to follow-up53
Withdrew: Death4145

Outcome measures

PrimaryRelapse-free Survival (RFS)

RFS was defined as the time from the date of randomization until the date of documented morphological relapse, or death from any cause, whichever occurred first. Morphological relapse was defined as documentation of any of the following events: * BM blasts ≥ 5% (not attributable to regenerating BM) * Any circulating blasts (not attributable to regenerating BM or growth factors) * Presence of extramedullary blast foci per Revised International Working Group (RIWG) criteria * The earliest date of any of the relapse event was used for RFS.

Time frame:
From the date of randomization up to 64 months and 22 days
Reported as:
Median · months
Relapse-free Survival (RFS)
monthsGilteritinibPlacebo
Relapse-free Survival (RFS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Gilteritinib vs Placebo · Log Rank · p = 0.0518 · Hazard ratio (hr): 0.679 · 95% CI 0.459 to 1.005
SecondaryOverall Survival (OS)

OS was defined as the time from randomization until the date of death from any cause (death date - first dose date + 1). For a Participant who were not known to have died by the end of study follow-up, OS was censored at the date of last contact (date of last contact - first dose date + 1).

Time frame:
From the date of randomization up to 64 months and 22 day
Reported as:
Median · months
Overall Survival (OS)
monthsGilteritinibPlacebo
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Gilteritinib vs Placebo · Log Rank · p = 0.4394 · Hazard ratio (hr): 0.846 · 95% CI 0.554 to 1.293
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAE)

An Adverse event (AE) was any untoward medical occurrence in a participant administered a study drug, and which did not have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether considered related to the medicinal product. TEAE defined as an AE event observed through 30 days after the last dose.

Time frame:
From the date of randomization through 30 days after the last dose, up to 25 months and 22 days
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAE)
participantsGilteritinibPlacebo
Number of Participants With Treatment Emergent Adverse Events (TEAE)175162
SecondaryKarnofsky Performance Status Scores

KPS scores of participants were reported. KPS was a standard way of measuring ability of cancer participants to perform ordinary tasks. It was 11 level score which ranged between 0-100%. 100 =Normal, no complaints, no evidence of disease 90 =Able to carry on normal activity, minor signs or symptoms of disease 80 =Normal activity with effort, some signs or symptoms of disease 70 =Care for self, unable to carry on normal activity or to do work 60 =Required occasional assistance but was able to care for most of his needs 50 =Required considerable assistance \& frequent medical care 40 =Disabled, required special care \& assistance 30 = Severely disabled, hospitalization indicated, although death not imminent 20 =Very sick, hospitalization necessary, active supportive treatment necessary 10 =moribund fatal processes progressing rapidly 0 =Dead.

Time frame:
Baseline, month 24
Reported as:
Mean · unit on a scale
Karnofsky Performance Status Scores
unit on a scaleGilteritinibPlacebo
Baseline84.20 ± 10.6584.73 ± 10.69
Month 2493.12 ± 8.3491.67 ± 9.48
SecondaryPercentage of Participants With Non-relapse Mortality (NRM)

NRM was defined as death from any cause other than relapse or disease progression (DP). Relapse was defined as documentation of any of the following events: * BM blasts ≥ 5% (not attributable to regenerating BM) * Any circulating blasts (not attributable to regenerating BM or growth factors) * Presence of extramedullary blast foci per RIWG criteria * The earliest date of any of the relapse event were used for RFS. DP: \>=20% increase in sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline, sum must also be absolute increase of \>=5 mm. Unequivocal progression of existing non-target lesions. Appearance of at least 1 new lesion. Incidence of NRM was estimated using the cumulative incidence function, treating relapse/progression as a competing risk.

Time frame:
From the date of randomization up to 64 months and 22 days
Reported as:
Number · percentage of participants
Percentage of Participants With Non-relapse Mortality (NRM)
percentage of participantsGilteritinibPlacebo
Percentage of Participants With Non-relapse Mortality (NRM)13.6 (8.9 to 19.2)6.6 (3.5 to 11.0)
Statistical analysis
  • Gilteritinib vs Placebo · Fine-Grays Model · p = 0.0209 · Hazard ratio (hr): 2.3080 · 95% CI 1.1352 to 4.6922
SecondaryEvent-free Survival (EFS)

EFS: Time from date of randomization until documented relapse, or premature discontinuation of treatment or initiation of other anti-leukemic treatment or death from any cause, whichever occurred first. Relapse was defined as documentation of any of following events: * BM blasts ≥ 5% (not attributable to regenerating BM) * Any circulating blasts (not attributable to regenerating BM or growth factors) * Presence of extramedullary blast foci per RIWG criteria * The earliest date of any of relapse event were used for RFS. Anti-leukemic treatment was defined as hypomethylating agents, chemotherapy, oral anticancer agents, Donor lymphocyte infusion (DLI) or cellular therapies given because of detectable disease, not meeting R-IWG criteria for relapse.

Time frame:
From the date of randomization up to 64 months and 22 days
Reported as:
Median · months
Event-free Survival (EFS)
monthsGilteritinibPlacebo
Event-free Survival (EFS)NA (19.65 to NA)NA (15.05 to NA)
Statistical analysis
  • Gilteritinib vs Placebo · Log Rank · p = 0.6417 · Hazard ratio (hr): 0.930 · 95% CI 0.686 to 1.261
SecondaryPercentage of Participants With Treatment Emergent Acute Graft vs. Host Disease (aGVHD)

The cumulative incidence at 6 months after randomization of grades II-IV and grades III-IV aGVHD were reported, treating death prior to aGVHD as the competing risk. It was graded according to diagnosis and severity scoring used by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). The acute GVHD algorithm calculated the grade based on the organ (skin, gastrointestinal (GI)and liver) stage and etiology/biopsy reported on the weekly GVHD form. Grade I aGVHD was defined as Skin stage of 1-2 and stage 0 for both GI and liver organs. Grade II aGVHD was stage 3 of skin, or stage 1 of GI, or stage 1 of liver. Grade III is stage 2-4 for GI, or stage 2-3 of liver. Grade IV was stage 4 of skin, or stage 4 of liver. Grade IV was the worst outcome. Treatment emergent was defined as an event observed through 30 days after the last dose.

Time frame:
From the date of randomization up to 6 months
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Emergent Acute Graft vs. Host Disease (aGVHD)
percentage of participantsGilteritinibPlacebo
aGVHD II to IV16.5 (11.3 to 22.5)19.2 (13.6 to 25.6)
aGVHD III to IV5.9 (3.0 to 10.1)4.1 (1.8 to 7.9)
Statistical analysis
  • Gilteritinib vs Placebo · Fine-Grays model · p = 0.6410 · Hazard ratio (hr): 0.8938 · 95% CI 0.5574 to 1.4330
  • Gilteritinib vs Placebo · Fine-Grays model · p = 0.4128 · Hazard ratio (hr): 1.4254 · 95% CI 0.6103 to 3.3289
SecondaryPercentage of Participants With Treatment Emergent Chronic GVHD at 12 Months

Chronic GVHD was graded according to diagnosis and severity scoring from the National Institute of Health (NIH) 2014 Consensus Criteria. Eight organs - skin, mouth, liver, upper and lower gastrointestinal, esophagus, lung, eye, and joint/fascia were scored on a 0-3 scale to reflect degree of chronic GVHD involvement, where 0 = no involvement/no symptoms \& 3 indicated the worst symptom. This system staged severity in each individual organ, and then a global score defined as mild, moderate or severe, based on number of organs involved and organ severity score was calculated. The cumulative incidence of chronic GVHD (mild, moderate, severe) at 12 months after randomization was reported, treating death prior to chronic GVHD as the competing risk. Treatment emergent was defined as an event observed through 30 days after the last dose.

Time frame:
From the date of randomization up to 12 months
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Emergent Chronic GVHD at 12 Months
percentage of participantsGilteritinibPlacebo
Percentage of Participants With Treatment Emergent Chronic GVHD at 12 Months57.0 (48.5 to 64.6)48.1 (39.5 to 56.2)
Statistical analysis
  • Gilteritinib vs Placebo · Fine-Grays Model · p = 0.1725 · Hazard ratio (hr): 1.2360 · 95% CI 0.9116 to 1.6757
SecondaryPercentage of Participants With Treatment Emergent Chronic GVHD at 24 Months

Chronic GVHD was graded according to diagnosis and severity scoring from the NIH 2014 Consensus Criteria. Eight organs- skin, mouth, liver, upper and lower gastrointestinal, esophagus, lung, eye, and joint/fascia are scored on a 0-3 scale to reflect degree of chronic GVHD involvement where 0 = no involvement/no symptoms \& 3 indicated the worst symptom. This system staged severity in each individual organ, and then a global score defined as mild, moderate or severe, based on number of organs involved and organ severity score was calculated. The cumulative incidence of chronic GVHD (mild, moderate, severe) at 24 months after randomization was reported, treating death prior to chronic GVHD as the competing risk. Treatment emergent was defined as an event observed through 30 days after the last dose.

Time frame:
From the date of randomization up to 24 months
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Emergent Chronic GVHD at 24 Months
percentage of participantsGilteritinibPlacebo
Percentage of Participants With Treatment Emergent Chronic GVHD at 24 Months61.9 (53.3 to 69.4)51.8 (42.9 to 59.9)
Statistical analysis
  • Gilteritinib vs Placebo · Fine-Grays Model · p = 0.1725 · Hazard ratio (hr): 1.2360 · 95% CI 0.9116 to 1.6757
SecondaryPercentage of Participants With FMS-like Tyrosine Kinase 3/Internal Tandem Duplication (FLT3/ITD) Minimal Residual Disease (MRD)

The presence of MRD was considered Detectable in participants who were FLT3/ITD MRD undetectable prior to randomization if log10-transformed overall FLT3/ITD mutation ratio greater than -4 otherwise presence of MRD was considered Not Detectable. Participants who had detectable FLT3/ITD MRD prior to randomization were considered eradicated if log10-transformed overall FLT3/ITD mutation ratio ≤ -4. Incidence of MRD Eradication and Detection were estimated using the cumulative incidence function, treating death during MRD assessment period without documentation of MRD event as competing risk.

Time frame:
From the date of randomization up to 64 months and 22 days
Reported as:
Number · percentage of participants
Percentage of Participants With FMS-like Tyrosine Kinase 3/Internal Tandem Duplication (FLT3/ITD) Minimal Residual Disease (MRD)
percentage of participantsGilteritinibPlacebo
MRD Eradication80 (4.7 to 98.4)NA (NA to NA)
MRD 10^-4 Detection7.1 (3.4 to 12.4)9.2 (5.0 to 15.0)
Statistical analysis
  • Gilteritinib vs Placebo · Fine-Grays Model · p = 0.2029 · Hazard ratio (hr): 3.4537 · 95% CI 0.5126 to 23.2687
  • Gilteritinib vs Placebo · Fine-Grays Model · p = 0.4077 · Hazard ratio (hr): 0.7073 · 95% CI 0.3116 to 1.6055
SecondaryPercentage of Participants With Relapse

Cumulative incidence of relapse was reported, treating death in remission as a competing risk. Relapse was defined as documentation of any of the following events: * BM blasts ≥ 5% (not attributable to regenerating BM) * Any circulating blasts (not attributable to regenerating BM or growth factors) * Presence of extramedullary blast foci per RIWG criteria * The earliest date of any of the relapse event were used for RFS.

Time frame:
From the date of randomization up to 64 months and 22 days
Reported as:
Number · percentage of participants
Percentage of Participants With Relapse
percentage of participantsGilteritinibPlacebo
Percentage of Participants With Relapse12.4 (7.9 to 17.8)26.7 (20.3 to 33.5)
Statistical analysis
  • Gilteritinib vs Placebo · Fine-Grays Model · p = <0.001 · Hazard ratio (hr): 0.3729 · 95% CI 0.2243 to 0.6199
SecondaryPercentage of Participants With Treatment Emergent Infection by Severity.

Severity of Infection was assessed based on the following criteria: Grade 1-Mild Asymptomatic or mild symptoms, clinical or diagnostic observations noted intervention not indicated. Grade 2-Moderate Local or noninvasive intervention indicated. Grade 3-Severe Medically significant but not immediately life threatening, hospitalization or prolonged hospitalization. Grade 4-Life Threatening Life threatening consequences, urgent intervention indicated. Grade 5-Death related to the AE. Cumulative incidence of grade 3 to 5 infections were reported, treating death (grade 5) as a competing event. Treatment emergent was defined as an event observed through 30 days after the last dose.

Time frame:
From the date of randomization through 30 days after the last dose, up to 25 months and 22 days
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Emergent Infection by Severity.
percentage of participantsGilteritinibPlacebo
Percentage of Participants With Treatment Emergent Infection by Severity.39.6 (31.3 to 47.8)27.2 (19.9 to 35.0)
Statistical analysis
  • Gilteritinib vs Placebo · Fine-Grays model · p = 0.0568 · Hazard ratio (hr): 1.4848 · 95% CI 0.9886 to 2.2300

Adverse events

Collected over All-cause mortality: From the date of randomization up to 64 months and 22 days Adverse events: From the date of randomization through 30 days after the last dose, up to 25 months and 22 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gilteritinib42/178 (23.6%)92/178 (51.7%)175/178 (98.3%)
Placebo44/177 (24.9%)81/177 (45.8%)169/177 (95.5%)
Most frequent serious events
Showing 10 of 173
Most frequent serious events
EventGilteritinibPlacebo
Acute graft versus host diseaseImmune system disorders19/17822/177
PneumoniaInfections and infestations16/1786/177
Chronic graft versus host diseaseImmune system disorders10/1788/177
Medication errorInjury, poisoning and procedural complications4/1786/177
Febrile neutropeniaBlood and lymphatic system disorders6/1782/177
Acute kidney injuryRenal and urinary disorders6/1784/177
Respiratory syncytial virus infectionInfections and infestations6/1783/177
Acute myeloid leukaemia recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1785/177
PyrexiaGeneral disorders4/1784/177
NeutropeniaBlood and lymphatic system disorders4/1781/177
Most frequent other events
Showing 10 of 57
Most frequent other events
EventGilteritinibPlacebo
Chronic graft versus host diseaseImmune system disorders94/17877/177
Acute graft versus host diseaseImmune system disorders67/17864/177
Neutrophil count decreasedInvestigations49/17817/177
DiarrhoeaGastrointestinal disorders44/17830/177
NauseaGastrointestinal disorders38/17840/177
Alanine aminotransferase increasedInvestigations33/17822/177
Blood creatine phosphokinase increasedInvestigations33/1783/177
CoughRespiratory, thoracic and mediastinal disorders33/17830/177
Platelet count decreasedInvestigations32/17817/177
AnaemiaBlood and lymphatic system disorders30/17820/177

Baseline characteristics

Intention-to-Treat (ITT) population: All randomized participants were included in this population

Age, Continuous
Age, Continuous(Years)GilteritinibPlaceboTotal
Mean50.3 ± 13.651.8 ± 12.351 ± 12.9
Sex: Female, Male
Sex: Female, Male(Participants)GilteritinibPlaceboTotal
Female8786173
Male9192183
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GilteritinibPlaceboTotal
Hispanic or Latino3912
Not Hispanic or Latino162162324
Unknown or Not Reported13720
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GilteritinibPlaceboTotal
American Indian or Alaska Native000
Asian4756103
Native Hawaiian or Other Pacific Islander000
Black or African American639
White114106220
More than one race000
Unknown or Not Reported111324
Number of participants with conditioning regimen intensity
Number of participants with conditioning regimen intensity(Participants)GilteritinibPlaceboTotal
MAC103103206
RIC/NMA7575150
Number of Participants With Time from first day of hematopoietic cell infusion to randomization
Number of Participants With Time from first day of hematopoietic cell infusion to randomization(Participants)GilteritinibPlaceboTotal
30-60 days9597192
61-90 days8381164
Presence of MRD
Presence of MRD(Participants)GilteritinibPlaceboTotal
Present343367
Absent/Unknown144145289
08

Study locations

118 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Mayo Clinic
    Phoenix, Arizona 85054, United States
  • Virginia G Piper Cancer Center
    Scottsdale, Arizona 85258, United States
  • University of California San Francisco
    San Francisco, California 94143, United States
  • Stanford University
    Stanford, California 94305, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06511, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • University of Miami
    Miami, Florida 33136, United States
  • H. Lee Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Northside
    Atlanta, Georgia 30342, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Indiana Blood and Marrow Transplant
    Indianapolis, Indiana 46237, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160-7233, United States
  • University of Maryland Medical Systems
    Baltimore, Maryland 21201, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21231, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Massachusetts
    Worcester, Massachusetts 01655, United States
  • Karmanos Cancer Center
    Detroit, Michigan 48201, United States
  • University of Minnesota School of Medicine
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University in St. Louis
    Saint Louis, Missouri 63110, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Memorial Sloan Kettering
    New York, New York 10065, United States
  • Weill Cornell Medical Center
    New York, New York 10065, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27599, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27157, United States
  • University Hospitals of Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Ohio State University, The
    Columbus, Ohio 43210, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84143, United States
  • Intermountain BMT
    Salt Lake City, Utah 84143, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • West Virginia University Hospital
    Morgantown, West Virginia 26506-9214, United States
  • University of Wisconsin Hospital and Clinics
    Madison, Wisconsin 53792, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Site AU61001
    Liverpool, Australia
  • Site AU61002
    Melbourne, Australia
  • Site AU61004
    Westmead, Australia
  • Site BE32003
    Bruxelles, Belgium
  • Site BE32004
    Gent, Belgium
  • Site CA15004
    Hamilton, Canada
  • Site CA15003
    Montreal, Canada
  • Site DK45002
    Arhus, Denmark
  • Site DK45001
    Copenhagen, Denmark
  • Site FR33007
    Lille, France
  • Site FR33004
    Lyon, France
  • Site FR33005
    Paris, France
  • Site FR33008
    Pessac, France
  • Site FR33010
    Vandoeuvre-Les-Nancy, France
  • Site DE49002
    Düsseldorf, Germany
  • Site DE49003
    Halle (Saale), Germany
  • Site DE49005
    Hamburg, Germany
  • Site DE49006
    Köln, Germany
  • Site DE49007
    Mainz, Germany
  • Site DE49004
    Münster, Germany
  • Site GR30004
    Athens, Greece
  • Site GR30003
    Rio, Greece
  • Site GR30001
    Thessaloniki, Greece
  • Site IT39005
    Bergamo, Italy
  • Site IT39006
    Bologna, Italy
  • Site IT39009
    Genova, 16132, Italy
  • Site IT39002
    Milano, Italy
  • Site IT39007
    Milano, Italy
  • Site IT39011
    Pescara, Italy
  • Site IT39003
    Roma, Italy
  • Site IT39004
    Udine, Italy
  • Site JP81014
    Anjo, Aichi, Japan
  • Site JP81011
    Nagoya, Aichi, Japan
  • Site JP81018
    Sapporo, Hokkaido, Japan
  • Site JP81021
    Kobe, Hyogo, Japan
  • Site JP81012
    Nishinomiya, Hyogo, Japan
  • Site JP81002
    Isehara, Kanagawa, Japan
  • Site JP81007
    Yokohama, Kanagawa, Japan
  • Site JP81010
    Sendai, Miyagi, Japan
  • Site JP81006
    Suita, Osaka, Japan
  • Site JP81008
    Shimotsuke, Tochigi, Japan
  • Site JP81013
    Bunkyo-ku, Tokyo, Japan
  • Site JP81004
    Chuo-ku, Tokyo, Japan
  • Site JP81016
    Minato-ku, Tokyo, Japan
  • Site JP81020
    Shinjuku-ku, Tokyo, Japan
  • Site JP81001
    Fukuoka, Japan
  • Site JP81003
    Fukuoka, Japan
  • Site JP81015
    Kyoto, Japan
  • Site JP81017
    Okayama, Japan
  • Site JP81005
    Osaka, Japan
  • Site KR82001
    Seoul, Korea, Republic of
  • Site KR82002
    Seoul, Korea, Republic of
  • Site KR82003
    Seoul, Korea, Republic of
  • Site KR82004
    Seoul, Korea, Republic of

Showing the first 100 of 118 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Jan 2023, 64 months.

Results were first posted in Sep 2024, 1 year 8 months after primary completion. A results delay was requested in Feb 2024.

Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 64 months is above that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2016
First posted
Dec 19, 2016
StartActual
Aug 16, 2017
Primary completionActual
Jan 7, 2023
CompletionActual
May 9, 2023
Results delay requested
Feb 28, 2024
Results first posted
Sep 19, 2024
Last update
Jan 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02997202
Collaborators
National Heart, Lung, and Blood Institute (NHLBI), Blood and Marrow Transplant Clinical Trials Network
Responsible party
Sponsor
First posted
Dec 19, 2016
Start date
Aug 16, 2017
Primary completion
Jan 7, 2023
Completion
May 9, 2023
Results posted
Sep 19, 2024
Last update
Jan 17, 2025

Study contacts

Senior Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gilteritinib

Start the discussion